(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/260579 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61K 45/06* (2006.01)
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/IB2021/055548

(22) International Filing Date:
23 June 2021 (23.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/043,498 24 June 2020 (24.06.2020) US

(71) Applicants: **ASTRAZENECA UK LIMITED** [GB/GB]; 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **DAIICHI SANKYO COMPANY, LIMITED** [JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8426 (JP).

(72) Inventors: **METTETAL II, Jerome Thomas**; c/o AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **DURANT, Stephen Thomas**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **ASTANEH, Azadeh Cheraghchi Bashi**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **LAU, Alan Yin Kai**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **WALLEZ, Yann**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).


(74) Agent: **FAIRBAIRN, Angus Chisholm**; Marks & Clerk LLP, 15 Fetter Lane, London EC4A 1BW (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR



(I)

(57) Abstract: A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):

WO 2021/260579 A1